

Financial news for ATRA dated on 2020-05-27: The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Financial news for ATRA dated on 2020-05-27: Atara Biotherapeutics Prices 12.6M Share Public Offering @\$11.32/Share

Financial news for ATRA dated on 2020-05-27: 96 Biggest Movers From Yesterday

Financial news for ATRA dated on 2020-05-26: Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants; No Terms Disclosed

Financial news for ATRA dated on 2020-05-26: 61 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ATRA dated on 2020-05-26: Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months With ATA188 In Patients With Progressive Multiple Sclerosis In Late-Breaking e-Poster At 2020 European Academy Of Neurology Virtual Congress

Financial news for ATRA dated on 2020-05-22: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetrphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

Financial news for ATRA dated on 2020-05-21: 70 Biggest Movers From Yesterday

Financial news for ATRA dated on 2020-05-20: Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.

Financial news for ATRA dated on 2020-05-19: Atara Biotherapeutics Highlights Will Present Late-Breaking ATA188 Data In Progressive Multiple Sclerosis At European Academy Of Neurology Virtual Congress

Financial news for ATRA dated on 2020-05-12: JP Morgan Maintains Neutral on Atara Biotherapeutics, Raises Price Target to \$23

Financial news for ATRA dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for ATRA dated on 2020-04-23: Atara Biotherapeutics shares are trading higher after Citigroup upgraded the stock from Neutral to Buy.

Financial news for ATRA dated on 2020-04-23: Citigroup Upgrades Atara Biotherapeutics to Buy

Financial news for ATRA dated on 2020-04-07: 56 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ATRA dated on 2020-04-02: Atara Biotherapeutics Says Remains On Track To Initiate tab-cel Biologics License Application Submission For Patients With EBV+ PTLID In H2'20

Financial news for ATRA dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for ATRA dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for ATRA dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for ATRA dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for ATRA dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for ATRA dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for ATRA dated on 2020-02-27: Atara Biotherapeutics Q4 EPS \$(1.36) Misses \$(1.34) Estimate

Financial news for ATRA dated on 2020-02-27: Atara Bio Filing Shows Registration For \$100M Common Stock Offering

Financial news for ATRA dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for ATRA dated on 2020-02-23: The Week Ahead In Biotech: Biopharma

Earnings Pick Up Pace

Financial news for ATRA dated on 2020-01-12: Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference

Financial news for ATRA dated on 2019-11-08: Benzinga's Top Upgrades, Downgrades For November 8, 2019

Financial news for ATRA dated on 2019-11-08: JP Morgan Downgrades Atara Biotherapeutics to Neutral, Lowers Price Target to \$22

Financial news for ATRA dated on 2019-11-07: Atara Biotherapeutics Earlier Reported Q3 EPS \$(1.31) Beats \$(1.44) Estimate

Financial news for ATRA dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for ATRA dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for ATRA dated on 2019-10-30: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ATRA dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for ATRA dated on 2019-10-25: Atara Biotherapeutics Chief Science Officer Reportedly Has Left Co.

Financial news for ATRA dated on 2019-10-15: 64 Biggest Movers From Yesterday

Financial news for ATRA dated on 2019-09-27: Benzinga's Top Upgrades, Downgrades For September 27, 2019

Financial news for ATRA dated on 2019-09-27: 21 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ATRA dated on 2019-09-27: Atara Biotherapeutics shares are trading lower after Goldman Sachs downgraded the stock from Neutral to Sell and lowered the price target from \$14 to \$9 per share.

Financial news for ATRA dated on 2019-09-27: 25 Stocks Moving in Friday's Pre-Market Session

Financial news for ATRA dated on 2019-09-27: Goldman Sachs Downgrades Atara Biotherapeutics to Sell, Lowers Price Target to \$9

Financial news for ATRA dated on 2019-09-16: Benzinga's Top Upgrades, Downgrades For September 16, 2019

Financial news for ATRA dated on 2019-09-16: 10 Biggest Price Target Changes For Monday

Financial news for ATRA dated on 2019-09-16: Jefferies Downgrades Atara Biotherapeutics to Hold, Lowers Price Target to \$15

Financial news for ATRA dated on 2019-09-13: The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

Financial news for ATRA dated on 2019-09-13: Atara Biotherapeutics Reports Early Findings Of Potential Efficacy From Phase 1 Study Of ATA188 In Patients With Progressive Multiple Sclerosis At ECTRIMS

Financial news for ATRA dated on 2019-09-11: Canaccord Maintains Buy, \$70 Tgt On Atara Biotherapeutics Ahead Of 'preliminary efficacy data at ECTRIMS on Friday, 9/13, in n=12 patients at 6 months of follow-up and will discuss changes in EDSS score, a key endpoint for progressive multiple sclerosis'

Financial news for ATRA dated on 2019-09-11: The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With \$260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway

Financial news for ATRA dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for ATRA dated on 2019-09-05: Shares of several healthcare companies are trading higher in sympathy with the overall market after the Chinese Minister of

Commerce said the leaders of the U.S. and China are set to meet in Washington D.C in early October. Investors hope the meeting could bring the two countries closer to a trade deal.

Financial news for ATRA dated on 2019-08-08: Atara Biotherapeutics Earlier Reported Q2 EPS \$(1.6) Misses \$(1.5) Estimate

Financial news for ATRA dated on 2019-08-07: Stocks That Fell Through 52-Week Lows Wednesday

Financial news for ATRA dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for ATRA dated on 2019-08-05: New 52-Week Lows For Monday Morning

Financial news for ATRA dated on 2019-08-02: Stocks That Set New 52-Week Lows Friday Morning

Financial news for ATRA dated on 2019-08-01: Stocks that Reached Yearly Lows Thursday Morning

Financial news for ATRA dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for ATRA dated on 2019-07-26: Stocks That Managed to Breach 52-Week Lows Friday

Financial news for ATRA dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for ATRA dated on 2019-07-19: Atara Biotherapeutics Prices Public 6.8M Share Offering of Common Stock @\$15.28/Share

Financial news for ATRA dated on 2019-07-18: Atara Biotherapeutics shares are trading lower after the company reported a \$125 million common stock offering.

Financial news for ATRA dated on 2019-07-18: Atara Biotherapeutics Reports \$125M Common Stock Offering

Financial news for ATRA dated on 2019-07-17: 58 Biggest Movers From Yesterday

Financial news for ATRA dated on 2019-07-16: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ATRA dated on 2019-07-16: Atara Biotherapeutics Announces Plan To Initiate Tab-cel FDA Biologics License Application Submission Next Year

Financial news for ATRA dated on 2019-07-11: The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug

Financial news for ATRA dated on 2019-07-09: The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering

Financial news for ATRA dated on 2019-06-30: Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive MS at #EAN2019

Financial news for ATRA dated on 2019-06-27: The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO

Financial news for ATRA dated on 2019-06-26: The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

Financial news for ATRA dated on 2019-06-05: Atara Biotherapeutics Intends To Provide Update Related To Ongoing Discussions With FDA Regarding Development Of Tab-Cel

Financial news for ATRA dated on 2019-06-04: Atara Biotherapeutics Reports Collaborators At Memorial Sloan Kettering Cancer Center Presented Updated Results From Ongoing MSK Phase 1 Study Of Mesothelin-Targeted CAR T Immunotherapy

Financial news for ATRA dated on 2019-06-04: Benzinga's Top Upgrades, Downgrades For June 4, 2019

Financial news for ATRA dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for ATRA dated on 2019-06-04: Citigroup Upgrades Atara Biotherapeutics to Neutral

Financial news for ATRA dated on 2019-06-01: Atara Biotherapeutics Presents Tab-cel Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at #ASCO19

Financial news for ATRA dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for ATRA dated on 2019-05-30: Benzinga's Top Upgrades, Downgrades For May 30, 2019

Financial news for ATRA dated on 2019-05-30: Roth Capital Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces \$30 Price Target

Financial news for ATRA dated on 2019-05-23: Stifel Nicolaus Initiates Coverage On Atara Biotherapeutics, Inc. - Common Stock with Buy Rating, Announces \$41 Price Target

Financial news for ATRA dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for ATRA dated on 2019-05-15: Atara Biotherapeutics Highlights Presentation Of Tab-cel(r), Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology

Financial news for ATRA dated on 2019-05-14: The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

Financial news for ATRA dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for ATRA dated on 2019-05-10: 82 Biggest Movers From Yesterday

Financial news for ATRA dated on 2019-05-09: 71 Stocks Moving In Thursday's Mid-Day Session

Financial news for ATRA dated on 2019-05-09: Atara Biotherapeutics Q1 EPS \$(1.44) Beats \$(1.51) Estimate

Financial news for ATRA dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for ATRA dated on 2019-04-18: Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.

Financial news for ATRA dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for ATRA dated on 2019-04-09: Atara Biotherapeutics Option Alert: Jun 21 \$45 Calls at the Ask: 2000 @ \$2.701 vs 2031 OI; Earnings 5/7 Before Open [est] Ref=\$37.98

Financial news for ATRA dated on 2019-03-31: Atara Biotherapeutics Announces Memorial Sloan Kettering Cancer Center Presented Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma at #AACR2019

Financial news for ATRA dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for ATRA dated on 2019-02-27: 72 Biggest Movers From Yesterday

Financial news for ATRA dated on 2019-02-26: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ATRA dated on 2019-02-26: Atara Biotherapeutics, Inc. - Common Stock Q4 EPS \$(1.75) Misses \$(1.31) Estimate

Financial news for ATRA dated on 2019-01-23: Benzinga's Top Upgrades, Downgrades For January 23, 2019

Financial news for ATRA dated on 2019-01-23: Mizuho Initiates Coverage On Atara Biotherapeutics with Buy Rating, Announces \$62 Price Target

Financial news for ATRA dated on 2019-01-04: 58 Biggest Movers From Yesterday

Financial news for ATRA dated on 2019-01-03: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for ATRA dated on 2019-01-03: Atara Biotherapeutics shares are trading lower after the company announced that CEO Isaac Ciechanover plans to step down.

Financial news for ATRA dated on 2019-01-03: Atara Biotherapeutics Reports Pres, CEO Isaac Ciechanover To Step Down; Co. Has Initiated Search To Find Replacement

Financial news for ATRA dated on 2019-01-03: Atara Biotherapeutics Reports Exclusivity On License For Mesothelin-Targeted CAR T Immunotherapy For Solid Tumors

Financial news for ATRA dated on 2019-01-03: Atara Biotherapeutics Exclusively Licenses Mesothelin-Targeted CAR T Immunotherapy For Solid Tumors

Financial news for ATRA dated on 2018-12-15: Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma at EMSO 2018

Financial news for ATRA dated on 2018-12-04: Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at ASH 2018

Financial news for ATRA dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for ATRA dated on 2018-11-19: Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus Immunotherapy

Financial news for ATRA dated on 2018-11-06: Atara Biotherapeutics Q3 EPS \$(1.29) Misses \$(1.13) Estimate

Financial news for ATRA dated on 2018-11-01: Atara Biotherapeutics Announces Presentations Highlighting Allogeneic T-Cell Immunotherapy Pipeline And CAR T Technologies At The 60th American Society of Hematology (ASH) Annual Meeting And European Society for Medical Oncology, Dec 13-16

Financial news for ATRA dated on 2018-09-06: Atara Biotherapeutics Reports Strategic Collaboration With Moffitt Cancer Center For Development Of Next-Gen CAR T Immunotherapies

Financial news for ATRA dated on 2018-08-01: Atara Biotherapeutics Q2 EPS \$(1.15) Down From \$(0.94) YoY

Financial news for ATRA dated on 2018-06-25: Atara Biotherapeutics Opens Operations and Manufacturing Facility In Thousand Oaks, CA

Financial news for ATRA dated on 2018-06-15: Atara Biotherapeutics Announces Tab-cel Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at #EHA2018

Financial news for ATRA dated on 2018-05-22: Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

Financial news for ATRA dated on 2018-05-08: Atara Biotherapeutics Reports Expansion Of Collaboration With Memorial Sloan Kettering Cancer Center To Develop Next Gen Of Genetically Engineered Chimeric Antigen Receptor T-Cell Immunotherapies

Financial news for ATRA dated on 2018-05-08: Atara Biotherapeutics Q1 EPS \$(1.05) Misses \$(0.92) Estimate

Financial news for ATRA dated on 2018-04-10: JP Morgan Initiates Coverage On Atara Biotherapeutics with Overweight Rating, Announces \$56.00 Price Target

Financial news for ATRA dated on 2018-03-16: Guggenheim Initiates Coverage On Atara Biotherapeutics with Neutral Rating

Financial news for ATRA dated on 2018-03-14: 45 Biggest Movers From Yesterday

Financial news for ATRA dated on 2018-03-01: Atara Biotherapeutics Reports Pricing Of ~4.286M Share Offering At \$35/Share

Financial news for ATRA dated on 2018-02-28: Benzinga's Top Upgrades, Downgrades For February 28, 2018

Financial news for ATRA dated on 2018-02-28: JMP Securities Downgrades Atara Biotherapeutics to Market Perform

Financial news for ATRA dated on 2018-02-27: Atara Biotherapeutics Reports Offering Of \$150M In Common Shares

Financial news for ATRA dated on 2018-02-27: Atara Biotherapeutics Filing Shows Registration For Mixed Securities Shelf Offering, No Amount Disclosed

Financial news for ATRA dated on 2018-02-27: Atara Biotherapeutics Reports Q4 EPS \$(1.15) vs \$(1.14) Est., No Sales

Financial news for ATRA dated on 2018-02-21: Atara Biotherapeutics CFO To Retire In April 2018

Financial news for ATRA dated on 2018-02-15: 40 Stocks Moving In Thursday's Mid-Day Session

Financial news for ATRA dated on 2018-02-15: Benzinga's Top Upgrades, Downgrades For February 15, 2018

Financial news for ATRA dated on 2018-02-15: Citigroup Downgrades Atara Biotherapeutics Inc to Sell

Financial news for ATRA dated on 2018-02-15: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for ATRA dated on 2018-02-14: 40 Biggest Movers From Yesterday

Financial news for ATRA dated on 2018-02-12: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for ATRA dated on 2018-02-05: 40 Biggest Movers From Friday

Financial news for ATRA dated on 2018-02-02: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for ATRA dated on 2018-01-29: 45 Biggest Movers From Friday

Financial news for ATRA dated on 2018-01-26: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for ATRA dated on 2018-01-26: Benzinga's Top Upgrades, Downgrades For January 26, 2018

Financial news for ATRA dated on 2018-01-26: Cowen & Co. Initiates Coverage On Atara Biotherapeutics with Outperform Rating

Financial news for ATRA dated on 2018-01-25: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for ATRA dated on 2018-01-16: 38 Biggest Movers From Friday

Financial news for ATRA dated on 2018-01-12: 33 Stocks Moving In Friday's Mid-Day Session

Financial news for ATRA dated on 2018-01-10: Atara Biotherapeutics Reports FDA Clearance To Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATAl88 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis

Financial news for ATRA dated on 2018-01-05: Atara Biotherapeutics 13G Filing From Camber Capital Shows Raised Stake From ~535.5K Shares At End Of Last Qtr. To 2.5M Shares, Or 6.65% Stake

Financial news for ATRA dated on 2018-01-04: Atara Biotherapeutics Prices 7M Share Offering @\$18.25/Share

Financial news for ATRA dated on 2018-01-03: Mid-Afternoon Market Update: Crude Oil Up 2%; Moneygram Shares Plummet

Financial news for ATRA dated on 2018-01-03: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ATRA dated on 2018-01-03: Mid-Day Market Update: SCANA Climbs Following Merger With Dominion Energy; Crispr Therapeutics Shares Slide

Financial news for ATRA dated on 2018-01-03: Mid-Morning Market Update: Markets Open Higher; Commercial Metals Profit Beats Estimates

Financial news for ATRA dated on 2018-01-03: Citigroup Upgrades Atara Biotherapeutics to Neutral

Financial news for ATRA dated on 2018-01-03: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ATRA dated on 2018-01-02: Atara Biotherapeutics Reports Offering Of \$100M In Common Stock

Financial news for ATRA dated on 2018-01-02: 26 Biggest Movers From Friday

Financial news for ATRA dated on 2017-12-29: Mid-Afternoon Market Update: Crude Oil Up 1%; Pareteum Shares Spike Higher

Financial news for ATRA dated on 2017-12-29: 26 Stocks Moving In Friday's Mid-Day Session

Financial news for ATRA dated on 2017-12-29: Mid-Day Market Update: ADTRAN Drops On Weak Q4 Guidance; Atara Biotherapeutics Shares Spike Higher

Financial news for ATRA dated on 2017-12-29: UPDATE: Jefferies On Atara Says 'We would Buy the stock'

Financial news for ATRA dated on 2017-12-29: Jefferies Comments On Atara Biotherapeutics (Shares Up 20% Fri.) In Mid-Day Note, Says 'Overhang Removed With Start of Phase III Trials...Full Speed Ahead'; Maintains Buy Rating, \$30 Price Target

Financial news for ATRA dated on 2017-12-29: Mid-Morning Market Update: Markets Edge Lower; MassRoots Is Going To Leverage Blockchain For The Cannabis Industry

Financial news for ATRA dated on 2017-12-29: Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder

Financial news for ATRA dated on 2017-12-11: UPDATE: Atara Says Expects To Initiate Phase 2 Studies With Tabelecleucel By End Of 2017

Financial news for ATRA dated on 2017-12-11: UPDATE: Atara Says Multicenter Clinical Findings In Patients With EBV+PTLD Consistent With Tabelecleucel Profile Observed In Phase 2 Studies

Financial news for ATRA dated on 2017-12-11: Atara Biotherapeutics Reports Updated Interim Results From Multicenter Expanded Access Study Of Tabelecleucel In Patients With Rituximab-Refractory EBV Associated PTLD At ASH

Financial news for ATRA dated on 2017-11-09: Atara Biotherapeutics Reports Q3 EPS \$(1.02) vs \$(0.98) Est.

Financial news for ATRA dated on 2017-10-26: Atara Biotherapeutics Reports Received Rare Pediatric Disease Designation From FDA For ATA230 For Treatment Of CMV Infection

Financial news for ATRA dated on 2017-10-26: Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230

Financial news for ATRA dated on 2017-10-25: Atara Biotherapeutics Reports 6 Of 10 Progressive MS Patients Experienced Clinical Improvements In Ongoing Phase 1 Study Of ATA190

Financial news for ATRA dated on 2017-10-25: Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190

Financial news for ATRA dated on 2017-10-19: Atara Biotherapeutics Begins 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA18

Financial news for ATRA dated on 2017-09-11: Atara Biotherapeutics Receives 'Positive' Health Canada Regulatory Feedback for ATA129

Financial news for ATRA dated on 2017-08-07: Atara Biotherapeutics Reports Q2 EPS \$(0.94) vs \$(0.89) Est.

Financial news for ATRA dated on 2017-06-23: 6 Biotech Stocks Jefferies Says Are Undervalued

Financial news for ATRA dated on 2017-04-21: Atara Bio Partners With Merck To Evaluate KEYTRUDA In Combination With ATAL29 In NPC

Financial news for ATRA dated on 2017-04-20: Atara Bio Reports Interim Results from Ongoing Phase 1 Trial, Says Encouraging Clinical Improvements Correlate With EBV Reactivity

Financial news for ATRA dated on 2017-03-27: Atara Biotherapeutics Reports \$75M Stock Offering

Financial news for ATRA dated on 2017-03-09: Atara Bio Reports Q4 EPS \$(0.63) vs. \$(0.75) YoY

Financial news for ATRA dated on 2017-01-03: Atara Bio Says Planning to Submit Conditional Marketing Application in 2018

Financial news for ATRA dated on 2016-12-13: 10 Biggest Mid-Day Gainers For Tuesday

Financial news for ATRA dated on 2016-12-12: Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, With Primary Endpoint Of MATCH And ALLELE Trials Being Objective Response Rate

Financial news for ATRA dated on 2016-12-03: Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus-specific Cytotoxic T Lymphocytes at ASH 2016

Financial news for ATRA dated on 2016-11-04: Atara Bio Reports Q3 EPS \$(0.78) vs. Est. \$(0.88)

Financial news for ATRA dated on 2016-11-04: 4 Stocks That Rallied Three Days On Increasing Volume

Financial news for ATRA dated on 2016-11-01: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ATRA dated on 2016-10-27: 15 Stocks Which Plummeted Three Days On Increasing Volume

Financial news for ATRA dated on 2016-10-24: Jefferies Assumes Atara Biotherapeutics, Inc. - Common Stock at Buy

Financial news for ATRA dated on 2016-10-18: Atara Bio Granted Access to Priority Medicines Regulatory Support for Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder

Financial news for ATRA dated on 2016-10-11: Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems

Financial news for ATRA dated on 2016-09-15: 15 Biggest Mid-Day Losers For Thursday

Financial news for ATRA dated on 2016-09-15: 7 Biggest Price Target Changes For Thursday

Financial news for ATRA dated on 2016-09-15: Benzinga's Top Downgrades

Financial news for ATRA dated on 2016-09-15: Atara Biotherapeutics Has 25% Downside

Financial news for ATRA dated on 2016-09-15: Goldman Sachs Downgrades Atara Biotherapeutics to Sell, Lowers PT to \$16.00

Financial news for ATRA dated on 2016-08-08: A Handful of Biotech Stocks Plunge After Disappointing Results

Financial news for ATRA dated on 2016-08-08: 12 Biggest Mid-Day Losers For Monday

Financial news for ATRA dated on 2016-08-08: Atara Bio Reports Q2 EPS \$(0.66) vs. Est. \$(0.61)

Financial news for ATRA dated on 2016-07-12: Atara Biotherapeutics Reports First Patient Dosing in Multi-Center Expanded Access Protocol for Study of EBV-CTLs in EBV-Associated Lymphomas, Lymphoproliferative Disorders

Financial news for ATRA dated on 2016-06-23: Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from EMA

Financial news for ATRA dated on 2016-06-07: Atara Bio Announces Clinical Trial Results for Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate

Financial news for ATRA dated on 2016-05-05: Atara Bio Reports Q1 EPS \$(0.58) vs \$(0.55) Est.

Financial news for ATRA dated on 2016-04-19: Atara Bio's Partner QIMR Berghofer Medical Research Report Positive Clinical Data For T-Cell Immunotherapy In INPC

Financial news for ATRA dated on 2016-03-23: Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder

Financial news for ATRA dated on 2016-03-16: Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the (AACR) Annual Meeting

Financial news for ATRA dated on 2016-03-03: Atara Bio Reports Q4 EPS \$(0.75) vs. Est. \$(0.48)

Financial news for ATRA dated on 2016-02-08: Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder

Financial news for ATRA dated on 2015-12-15: China Finance Online, Heartland Payment Systems Lead Tuesday's After-Hours Movers

Financial news for ATRA dated on 2015-12-15: Citigroup Downgrades Atara Biotherapeutics to Sell, Lowers PT to \$16.00

Financial news for ATRA dated on 2015-12-14: Mid-Afternoon Market Update: Crude Oil Rises Over 2%; GoPro Shares Decline Following Morgan Stanley Downgrade

Financial news for ATRA dated on 2015-12-14: Mid-Day Market Update: Trina Solar Surges Following Announcement of Going Private Proposal; Newell Rubbermaid Shares Slip

Financial news for ATRA dated on 2015-12-14: Mid-Morning Market Update: Markets Mostly Flat; Newell Rubbermaid To Buy Jarden

Financial news for ATRA dated on 2015-12-14: Benzinga's Top #PreMarket Losers

Financial news for ATRA dated on 2015-12-06: Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL)

Financial news for ATRA dated on 2015-12-05: Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms' Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies

Financial news for ATRA dated on 2015-11-18: Goldman Sachs Assumes Atara Biotherapeutics at Neutral, Announces \$38.00 PT

Financial news for ATRA dated on 2015-10-21: Atara Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Exclusive License and Research Agreements

Financial news for ATRA dated on 2015-10-20: Atara Bio Receives FDA Orphan Drug Designation for STM 434 for Ovarian Cancer

Financial news for ATRA dated on 2015-10-05: Atara Bio's PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet

Financial news for ATRA dated on 2015-09-24: Atara Bio's T-Cell Product Candidate Activated Against Wilms' Tumor 1 Protein Demonstrates Encouraging Results in Patients With Plasma Cell Leukemia

Financial news for ATRA dated on 2015-09-09: Benzinga's Top Initiations

Financial news for ATRA dated on 2015-09-09: Buy Atara's T-Cell Potential, Stock Could Nearly Double: Canaccord

Financial news for ATRA dated on 2015-08-31: US Stock Futures Signal Lower Start On Wall Street

Financial news for ATRA dated on 2015-08-31: Atara Biotherapeutics Announces Completion of Enrollment in PINTA 745 Phase 2 Clinical Trial in End-Stage Renal Disease Patients With Protein Energy Wasting

Financial news for ATRA dated on 2015-08-06: Atara Biotherapeutics Reports Q2 Loss \$0.62 Vs Est Loss \$0.44

Financial news for ATRA dated on 2015-07-10: Mid-Morning Market Update: Markets Surge; PriceSmart Posts Mixed Results

Financial news for ATRA dated on 2015-07-10: Morning Market Losers

Financial news for ATRA dated on 2015-07-10: Benzinga's Top #PreMarket Losers

Financial news for ATRA dated on 2015-07-10: US Stock Futures Surge Ahead Of Wholesale Inventories Report

Financial news for ATRA dated on 2015-07-10: Atara Bio Prices ~3.46M Share Offering @\$52.00/Share

Financial news for ATRA dated on 2015-07-09: Amended S-1 from Atara Biotherapeutics Shows Increased Initial Value from \$125M to \$172.5M

Financial news for ATRA dated on 2015-07-07: Atara Bio Announces \$125M Secondary Offering

Financial news for ATRA dated on 2015-06-15: Atara Biotherapeutics Exercises Exclusive License to T-Cell Technology From Memorial Sloan Kettering Cancer Center

Financial news for ATRA dated on 2015-05-19: 7 Biotech Stocks Moving Off The UBS Healthcare Conference

Financial news for ATRA dated on 2015-05-07: Atara Biotherapeutics Reports Q1 Loss \$0.42 Vs Est Loss \$0.44

Financial news for ATRA dated on 2015-04-20: EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015

Financial news for ATRA dated on 2015-04-19: Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at Clinical Trials Plenary Session at AACR Annual Meeting

Financial news for ATRA dated on 2015-04-09: 13G Filing From Baupost Group Reports An Increased Stake In Atara Biotherapeutics From 10.25% To 19.6%

Financial news for ATRA dated on 2015-04-01: Amgen Reports 6% Passive Stake in Atara Biotherapeutics as of Oct 16, 2014

Financial news for ATRA dated on 2015-03-02: Atara Reports FDA Grants Breakthrough Therapy Designation to EBV Targeted T-Cells for Treatment of EBV-LPD

Financial news for ATRA dated on 2015-02-12: Atara Bio Prices \$65.5M Offering of Common Stock

Financial news for ATRA dated on 2015-02-09: Atara Bio Reports Offering of 3M Common Shares

Financial news for ATRA dated on 2014-11-12: Atara Biotherapeutics Reports Q3 EPS of \$(4.20)

Financial news for ATRA dated on 2014-11-10: UPDATE: Citigroup Initiates Coverage On Atara Biotherapeutics On New Lead Product Candidates

Financial news for ATRA dated on 2014-11-10: Benzinga's Top Initiations

Financial news for ATRA dated on 2014-11-10: Citigroup Initiates Coverage on Atara Biotherapeutics at Buy, Announces \$37.00 PT

Financial news for ATRA dated on 2014-11-10: Jefferies Initiates Atara Biotherapeutics At Buy

Financial news for ATRA dated on 2014-11-10: Jefferies Initiates Coverage on Atara Biotherapeutics at Buy, Announces \$35.00 PT

Financial news for ATRA dated on 2014-11-10: Goldman Sachs Initiates Coverage on Atara Biotherapeutics at Neutral, Announces \$30.00 PT

Financial news for ATRA dated on 2014-10-16: IPO for Atara Biotherapeutics Opens at \$9.89, IPO Priced at \$11/Share

Financial news for ATRA dated on 2014-10-16: Expected IPOs For October 16

Financial news for ATRA dated on 2014-10-16: Atara Biotherapeutics Prices 5M Share IPO @\$11.00/Share

Financial news for ATRA dated on 2014-07-21: IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?

Financial news for ATRA dated on 2014-07-10: Atara Biotherepeutics Prices 5M Share IPO From \$14 to \$16

Financial news for ATRA dated on 2014-06-20: Atara Biotherapeutics Files Up to \$50M IPO